OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 00:01 UTC. Every row links to its source record.

STAG2 STAG2 cohesin complex component

ENSG00000101972 · protein coding · Open Targets profile

Component of cohesin complex, a complex required for the cohesion of sister chromatids after DNA replication. The cohesin complex apparently forms a large proteinaceous ring within which sister chromatids can be trapped. At anaphase, the complex is cleaved and dissociates from chromatin, allowing sister chromatids to segregate. The cohesin complex may also play a role in spindle pole assembly during mitosis. .

In 15 of 15 cancers, the evidence for STAG2 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751urinary bladder cancerurinary bladder cancerurinary bladder cancer: somatic 0.85Ewing sarcomaEwing sarcomaEwing sarcoma: somatic 0.82acute myeloid leukemiaacute myeloid leukemiaacute myeloid leukemia: somatic 0.52myelodysplastic syndromemyelodysplastic syndromemyelodysplastic syndrome: somatic 0.61urinary bladder carcinomaurinary bladder carcinomaurinary bladder carcinoma: somatic 0.61glioblastomaglioblastomaglioblastoma: somatic 0.61bladder transitional cell carcinomabladder transitional cell carcinomabladder transitional cell carcinoma: somatic 0.61lymphoid neoplasmlymphoid neoplasmlymphoid neoplasm: somatic 0.61HER2 positive breast carcinomaHER2 positive breast carcinomaHER2 positive breast carcinoma: somatic 0.61bile duct carcinomabile duct carcinomabile duct carcinoma: somatic 0.61endometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinoma: somatic 0.61Ewing sarcoma/peripheral primitive neur…Ewing sarcoma/peripheral primitive neuroectodermal tumor of boneEwing sarcoma/peripheral primitive neuroectodermal tumor of bone: somatic 0.61breast ductal adenocarcinomabreast ductal adenocarcinomabreast ductal adenocarcinoma: somatic 0.61hemangioblastomahemangioblastomahemangioblastoma: somatic 0.61ovarian endometrioid adenocarcinoma wit…ovarian endometrioid adenocarcinoma with squamous differentiationovarian endometrioid adenocarcinoma with squamous differentiation: somatic 0.61

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

PROTAC
Database Ubiquitination, Half-life Data

gnomAD loss of function constraint: o/e 0.12953999638557434 (upper bound 0.20250999927520752). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of STAG2's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of STAG2's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.